Literature DB >> 7436157

Rheumatoid vasculitis: effect of cyclophosphamide on the clinical course and levels of circulating immune complexes.

T Abel, B S Andrews, P H Cunningham, C M Brunner, J S Davis, D A Horwitz.   

Abstract

A study of five patients with severe rheumatoid vasculitis treated with cyclophosphamide was undertaken to determine whether immune complexes were present in serum and if their levels correlated with disease activity and response to treatment. Circulating immune complexes were measured by various techniques including the Clq binding and Raji cell radioimmunoassays and determination of the presence of cryoglobulins. Elevated levels of circulating immune complexes, hypocomplementemia, and high titer rheumatoid factor were present during active vasculitis. Clinical and serologic remissions were induced in all patients on cyclophosphamide. In two patients in remission, a rise in rheumatoid factor titer and immune complex levels was associated with an exacerbation of vasculitis and resolved on increased cyclophosphamide dosage. The Clq binding assay and rheumatoid factor titer correlated best with clinical activity. Thus, circulating immune complexes appear to be involved in the immunopathogenesis of rheumatoid vasculitis, which can be successfully treated with cyclophosphamide.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7436157     DOI: 10.7326/0003-4819-93-3-407

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  10 in total

1.  Rheumatoid vasculitis.

Authors:  D G Scott; P A Bacon
Journal:  Clin Rheumatol       Date:  1983-12       Impact factor: 2.980

2.  Complement (C3) metabolism in rheumatoid arthritis in relation to the disease course.

Authors:  A J Swaak; H Han; A van Rooyen; M Pillay; C E Hack
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

3.  Serum immune complexes containing IgA appear to predict erosive arthritis in a longitudinal study in rheumatoid arthritis.

Authors:  M L Westedt; M R Daha; W M Baldwin; T Stijnen; A Cats
Journal:  Ann Rheum Dis       Date:  1986-10       Impact factor: 19.103

4.  Rheumatoid vasculitis: diagnostic and therapeutic decisions.

Authors:  R S Panush; P Katz; S Longley; J Love; H Stanley
Journal:  Clin Rheumatol       Date:  1983-12       Impact factor: 2.980

5.  Rheumatoid vasculitis of the colon presenting as pancolitis.

Authors:  R W Burt; M M Berenson; C O Samuelson; W J Cathey
Journal:  Dig Dis Sci       Date:  1983-02       Impact factor: 3.199

6.  Clinical and serological features of severe vasculitis in rheumatoid arthritis: prognostic implications.

Authors:  A J Geirsson; G Sturfelt; L Truedsson
Journal:  Ann Rheum Dis       Date:  1987-10       Impact factor: 19.103

7.  Detection and partial characterization of immune complexes in patients with rheumatoid arthritis plus Sjogren's syndrome and with Sjogren's syndrome alone.

Authors:  S Yoshinoya; S McDuffy; D Alarcon-Segovia; R M Pope
Journal:  Clin Exp Immunol       Date:  1982-05       Impact factor: 4.330

8.  Correlation of antibody to rheumatoid arthritis associated nuclear antigen and immune complexes to disease activity in patients with rheumatoid arthritis.

Authors:  M A Alspaugh; D Rosenstock; J J Biundo; R C Gupta
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

9.  Connective Tissue Disease-associated Interstitial Lung Disease: A review.

Authors:  Markus Gutsche; Glenn D Rosen; Jeffrey J Swigris
Journal:  Curr Respir Care Rep       Date:  2012-09-21

10.  Cyclophosphamide treatment in polyarteritis nodosa.

Authors:  P Oriente; A Riccio; C Farinaro; E Farinaro; R Scarpa; L Vignone; A Pucino
Journal:  Clin Rheumatol       Date:  1986-06       Impact factor: 2.980

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.